Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use

Journal of Clinical Psychiatry

Volumn 64, Issue 12, 2003, Pages 1440-1448

  Shoptaw, Steven ^a,b,c   Yang, Xiaowei ^a   Rotheram Fuller, Erin J ^a,b   Hsieh, Ya Ching M ^a   Kintaudi, Prudencia C ^b   Charuvastra, V C ^b   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FRIENDS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZOYLECGONINE; COCAINE; PLACEBO; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RETENTION; DRUG SCREENING; DRUG USE; HUMAN; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS; ADULT; FEMALE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; SUBSTANCE ABUSE; URINE;

ADULT; BACLOFEN; COCAINE; COCAINE-RELATED DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GABA AGONISTS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME;

EID: 1342328633     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n1207     Document Type: Article

References (40)

1. Ling W, Shoptaw S. Integration of research in pharmacotherapy for addictive disease: where are we? where are we going? In: Miller NS, Stimmel B. Binghamton NY, eds. The Integration of Pharmacological and Nonpharmacological Treatments in Drug/Alcohol Addictions. The Haworth Press, Inc.; 1997:83-102
2. Self DW, Nestler EJ. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 1995;18:463-495
3. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 1999;146: 373-390
4. Kleber HD. Treatment of cocaine abuse: pharmacotherapy. CIBA Foundation Symposium 1992;166:195-200
5. Wise RA. D1-and D2-type contributions to psychomotor sensitization and reward: implications for pharmacological treatment strategies. Clin Neuropharmacol 1995;18:S74-S83
6. Cameron DL, Williams JT. Dopamine D1 receptors facilitate transmitter release. Nature 1993;366:344-347
7. Engberg G, Klingpetersen T, Nissbrandt H. GABA(B) receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. Synapse 1993;15:229-238
8. Klitenick MA, De Witte P, Kalivas PW. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J Neurosci 1992;12:2623-2632
9. Rick CE, Lacey MG. Rat sustantia nigra pars reticulata neurons are tonically inhibited via GABBA, but not GABAB, receptors in vitro. Brain Res 1994;659:133-137
10. Seutin V, Johnson SW, North RA. Effect of dopamine and baclofen on N-methyl-D-asparate induced burst firing in rat ventral tegmental neurons. Neuroscience 1994;58:201-206
11. Santiago M, Cano J, Westerink BHC. Are bilateral nigrostriatal dopaminergic pathways functionally linked in the rat brain: a microdialysis study in conscious rats. Brain Res 1993;628:187-192
12. Santiago M, Machado A, Cano J. Regulation of the prefrontal cortical dopamine release by GABAA and GABAB receptor agonists and antagonists. Brain Res 1993;630:8-31
13. Santiago M, Machado A, Cano J. In vivo release of dopamine from rat striatum, substantia nigra and prefrontal cortex: differential modulation by baclofen. Br J Pharmacol 1993;109:814-818
14. Kushner SA, Dewey SL, Kometsky C. Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology (Berl) 1997;133:383-388
15. Kushner SA, Unterwald EM. Chronic cocaine administration decreases the functional coupling of GABA(B) receptors in the rat ventral tegmental area as measured by baclofen-stimulated 35S-GTPgammaS binding. Life Sci 2001;69:1093-1102
16. Wood PL. Actions of GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat. J Pharmacol Exp Ther 1982;222: 674-679
17. Pycock C, Horton R. Evidence for an accumbens-pallidal pathway in the rat and its possible gabaminergic control. Brain Res 1976;110:629-634
18. Cousins MS, Roberts DC, de Wit H. GABA(B) receptors agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002;65:209-220
19. Morgan AE, Dewey SL. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extra cellular dopamine. Synapse 1998;28:60-65
20. Stromberg MF, Mackler SA, Volpicelli JR, et al. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol Biochem Behav 2001;68:291-299
21. Molina PE, Ahmed N, Ajmal M, et al. Co-administration of gamma-vinyl GABA and cocaine: preclinical assessment of safety. Life Sci 1999;65:1175-1182
22. Harding GF, Spencer EL, Wild JM, et al. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 2002;58:1261-1265
23. Roberts DC, Brebner K. GABA modulation of cocaine self-administration. Ann NY Acad Sci 2000;909:145-158
24. Brebner K, Phelan R, Roberts DC. Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 progressive-ratio schedules. Psychopharmacology (Berl) 2000;148:314-321
25. Roberts DC, Andrews MM, Vickers GJ. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology 1996;14:1-7
26. Campbell UC, Lac ST, Carroll ME. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology (Berl) 1999;143:209-214
27. Ling W, Shoptaw S, Majewska D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study Neuropsychopharmacology 1998;18:403-404
28. McLellan AT, Kushner H, Metzger D. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9:199-213
29. Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for the DSM-IV (SCID). Washington DC: American Psychiatric Press, 1995
30. Preston KL, Silverman K, Schuster CR, et al. Use of quantitative urinalysis in monitoring cocaine use. NIDA Res Monogr 1997;175: 253-264
31. Ling W, Shoptaw S, Wesson D, et al. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr 1997;175: 208-220
32. Gawin FH, Morgan C, Kosten TR, et al. Double-blind evaluation of the effect of acute amantadine on cocaine craving. Psychopharmacology (Berl) 1989;97:402-403
33. Rawson RA, Shoptaw SJ, Obert JL, et al. An intensive outpatient approach for cocaine abuse treatment. The Matrix model. J Subst Abuse Treat 1995;12:117-127
34. Shoptaw SJ, Rawson RA, McCann MJ, et al. The Matrix model of outpatient stimulant abuse treatment: evidence of efficacy. J Addict Dis 1995;13:23-35
35. Shoptaw SJ, Kintaudi PC, Charuvastra C, et al. A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend 2002;66:217-224
36. Guilford JP, Fruchter B. Fundamental Statistics in Psychology and Education, 6th ed. New York, NY: McGraw-Hill; 1978:159-163
37. Liang KY, Zeger SL. On the use of concordant pairs in matched case-controlled studies. Biometrics 1988;44:1145-1156
38. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-1060
39. Stram DO, Wei LJ, Ware JH. Analysis of repeated ordered categorical outcomes with possibly missing observations and time dependent covariates. J Am Stat Assoc 1988;83:631-637
40. Kampman KM, Volpicelli JR, Alterman AI, et al. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry 2000;157:2052-2054